—

annul the Commission’s decision of 7 February 2022 to reject the applicant’s request for access to documents of the Commission by refusing to provide him with copies of all of the correspondence that it has exchanged, since 1 April 2020, with the company AstraZeneca plc or with its subsidiaries as well as with the Federal Chancellery of Germany or with the Federal Ministry of Health, relating to the company AstraZeneca plc or its subsidiaries, and in particular to the quantity of Covid-19 vaccines offered by AstraZeneca plc and its delivery deadlines;

—

order the defendant to pay the costs of the proceedings.

1.

First plea in law: The applicant has a right to access the European Commission documents at issue pursuant to Article 2(1) of Regulation (EC) No 1049/2001. (1) The refusal by the Commission infringes that provision.

2.

Second plea in law: The ground for exclusion laid down in the second indent of Article 4(2) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. That ground for exclusion is limited in time and applies only to pending court proceedings and legal advice. The proceedings pending in Belgium against AstraZeneca under No 2021/48/C relate to a substantially different set of facts and have already been disposed of by the judgment of 18 June 2021.

3.

Third plea in law: The ground for exclusion laid down in Article 4(1)(b) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. The public interest in the disclosure of personal data prevails.

4.

Fourth plea in law: The ground for exclusion laid down in the first indent of Article 4(2) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. The requested information does not contain any trade secrets within the meaning of Article 2 of Directive (EU) 2016/943, (2) as it is known and there have been no reasonable steps to keep it secret.